About Thalivia

Expert-Led, Clinically Validated

Thalivia is a medical SaaS platform designed to transform intrathecal analgesia prescription and management. Developed in close collaboration with leading pain specialists, our solution addresses real clinical needs with rigorous safety standards and regulatory compliance.

Leadership & Medical Expertise

Medical Advisor: Dr. Denis Dupoiron, MD

Dr. Dupoiron is the founding medical expert behind Thalivia. As Head of the Pain Department at Institut de Cancérologie de l’Ouest (Angers, France), he leads Europe’s premier center for intrathecal analgesia.

Key credentials:

• Prix Axel Kahn 2023 laureate (awarded by Ligue contre le Cancer for outstanding contributions to cancer pain management)
• 50+ peer-reviewed publications in pain medicine and neuromodulation
• National expert mandated by the French Health Authority (HAS) and SFETD to draft official guidelines on intrathecal therapy
• 12+ years of clinical data published in leading journals (Regional Anesthesia & Pain Medicine, Neuromodulation, Pain Medicine)

Selected publications:

• Intrathecal cervical analgesia for cancer pain: a 12-year follow-up study (2023)
• Management of Cancer-Related Pain With Intrathecal Drug Delivery: A Systematic Review and Meta-Analysis (2022)
• Intrathecal Drug Delivery Systems for Refractory Pancreatic Cancer Pain: 11-Year Observational Study (2018)

Dr. Dupoiron’s expertise ensures that Thalivia reflects the highest standards of clinical practice, safety, and evidence-based medicine.

Supported by Leading Innovation Programs

Thalivia is backed by a network of French and European innovation accelerators:

• Bpifrance (BPI) – Public investment bank supporting deep-tech and health innovation
• Le Poool (French Tech Rennes) – Startup acceleration and digital health expertise
• Collectif Tactiques – Strategic design and product validation
• Bretagne Commerce International – International expansion support

This ecosystem validates Thalivia’s strategic positioning at the intersection of medical innovation, regulatory compliance, and European health tech.

Market Opportunity

Intrathecal analgesia is a specialized but growing field in pain management, particularly for cancer pain and chronic refractory conditions. Despite its clinical effectiveness, IT therapy suffers from a lack of standardized digital tools.

Current Market:

• ~20 specialized pain centers in France perform intrathecal therapy regularly
• 50-100+ centers across Europe (Spain, Germany, UK, Italy, Benelux)
• Global intrathecal therapy market growing at 7.2% CAGR, driven by aging populations and increasing cancer incidence
• No existing SaaS solution specifically designed for IT prescription workflows

The Problem: Today, most IT prescriptions are managed through:

• Paper-based protocols (error-prone, no traceability)
• Generic EMR systems (not adapted to IT complexity)
• Excel spreadsheets (no compliance, no collaboration)

This creates risks in:

• Prescription errors (dose calculations, drug interactions)
• Regulatory compliance (HAS guidelines, ANSM requirements, traceability)
• Knowledge transfer (mentoring junior physicians, standardizing practices)

Why Thalivia:

• Regulatory compliance: Built-in HAS/SFETD guidelines, full traceability
• Safety: Automated dose calculations, drug interaction alerts, protocol validation
• Collaboration: Peer review, mentoring tools, anonymized case sharing
• Efficiency: Structured workflows reduce prescription time and administrative burden

As regulatory pressure increases (HAS recommendations since 2020, ANSM safety monitoring), pain centers need compliant, structured tools. Thalivia addresses this unmet need with a solution co-designed by the leading European expert in the field.

Built for Real-World Clinical Practice

Every feature in Thalivia has been designed, tested, and refined with input from practicing pain specialists. From dose calculation to pharmacy workflows, we prioritize usability, safety, and compliance.

Our mission: Make intrathecal analgesia safer, more structured, and accessible to pain teams across Europe—while contributing to open science and evidence-based care.

Questions? Want to join as an early adopter? Contact us to learn more or request a demo.